Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 23, 2017
Pharmacy Choice - Pharmaceutical News - Landmark trial is using PET scans to diagnose Alzheimer's disease - October 23, 2017

Pharmacy News Article

 8/20/17 - Landmark trial is using PET scans to diagnose Alzheimer's disease

By a News Reporter-Staff News Editor at VerticalNews Health & Science MAYWOOD, IL - Loyola Medicine is participating in a landmark $100 million study of the effectiveness of using PET scans to detect Alzheimer's disease.

Alzheimer's disease has been linked to clumps of amyloid proteins, which block signals in the brain. PET, which stands for positron emission tomography, can detect amyloid plaques.

In a PET scan, a tracer drug is injected into the patient and the drug is taken up by any amyloid plaques in the brain. Attached to the drug is a slightly radioactive tracer, which emits a small amount of energy in the form of gamma rays. The PET scan detects this energy and a computer produces a detailed image. The tracer drug has been approved by the U.S. Food & Drug Administration.

It is difficult to make a definitive diagnosis of Alzheimer's disease. The study will examine how PET scans affect treatment. Researchers hypothesize that PET scans will decrease uncertainty and increase confidence in the underlying cause of a patient's cognitive impairment. This would lead to earlier counseling and interventions, resulting in improved outcomes.

Researchers will examine whether PET scans affect drug therapy and counseling about safety and future planning, and whether the test improves outcomes by reducing hospital and emergency department admissions. The findings will inform the Centers for Medicare & Medicaid Services in deciding whether to cover PET scans in dementia care.

The multi-center nationwide study will enroll 18,488 Medicare beneficiaries who have been diagnosed with mild cognitive impairment or dementia of unknown cause.

The study is sponsored by the American College of Radiology Imaging Network, in collaboration with the Alzheimer's Association. It is titled, "Imaging Dementia - Evidence for Amyloid Scanning (IDEAS)". Principal investigators at the Loyola site are Moises Gaviria, MD, a specialist in neuropsychiatry, and Robert Wagner, MD, medical director of nuclear medicine.

Keywords for this news article include: Amyloid, Dementia, Medicare, Proteins, Tauopathies, Health Policy, Brain Diseases and Conditions, Loyola University Health System, Central Nervous System Diseases and Conditions, Neurodegenerative Diseases and Conditions - Alzheimer Disease.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Oct 23: Vitamin D Primer for Pharmacy Professionals
Last Chance
Oct 24: Metabolic Syndrome: The Heart of Any Wellness Practice
Oct 25: Dispensing Controlled Substances in Today’s Pharmacy
Oct 26: Management of Schizophrenia & Acute Agitation
Oct 27: Influenza 2017-2018: An Update on Prevention and Treatment
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415